Regenxbio (NASDAQ:RGNX) Upgraded by TheStreet to C-

Share on StockTwits

TheStreet upgraded shares of Regenxbio (NASDAQ:RGNX) from a d+ rating to a c- rating in a research report sent to investors on Tuesday, TheStreetRatingsTable reports.

A number of other equities analysts have also recently commented on the stock. Zacks Investment Research cut shares of Regenxbio from a hold rating to a sell rating in a research report on Wednesday, February 5th. Evercore ISI reiterated a buy rating and issued a $65.00 target price on shares of Regenxbio in a research report on Monday, November 11th. Chardan Capital reiterated a buy rating and issued a $150.00 target price on shares of Regenxbio in a research report on Wednesday, January 29th. BidaskClub upgraded shares of Regenxbio from a buy rating to a strong-buy rating in a research report on Thursday. Finally, ValuEngine cut shares of Regenxbio from a strong-buy rating to a buy rating in a research report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $71.00.

Shares of NASDAQ:RGNX opened at $53.80 on Tuesday. The stock has a market cap of $1.98 billion, a PE ratio of -30.57 and a beta of 0.83. The company’s fifty day moving average is $45.23 and its 200 day moving average is $40.27. Regenxbio has a 52 week low of $30.38 and a 52 week high of $63.21. The company has a quick ratio of 11.49, a current ratio of 11.49 and a debt-to-equity ratio of 0.01.

In other Regenxbio news, SVP Curran Simpson sold 5,922 shares of the firm’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $50.00, for a total value of $296,100.00. Following the sale, the senior vice president now owns 25,570 shares of the company’s stock, valued at approximately $1,278,500. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Vittal Vasista sold 2,394 shares of the firm’s stock in a transaction on Friday, January 17th. The stock was sold at an average price of $50.00, for a total transaction of $119,700.00. Following the completion of the sale, the chief financial officer now directly owns 222,321 shares in the company, valued at approximately $11,116,050. The disclosure for this sale can be found here. In the last three months, insiders sold 49,016 shares of company stock worth $2,256,957. Insiders own 13.80% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. Amalgamated Bank grew its holdings in Regenxbio by 4.1% in the 4th quarter. Amalgamated Bank now owns 6,436 shares of the biotechnology company’s stock worth $264,000 after acquiring an additional 254 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in Regenxbio by 7.8% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,763 shares of the biotechnology company’s stock worth $147,000 after acquiring an additional 271 shares during the last quarter. Mason Street Advisors LLC grew its holdings in Regenxbio by 3.4% in the 3rd quarter. Mason Street Advisors LLC now owns 10,623 shares of the biotechnology company’s stock worth $378,000 after acquiring an additional 350 shares during the last quarter. Municipal Employees Retirement System of Michigan grew its holdings in Regenxbio by 3.8% in the 4th quarter. Municipal Employees Retirement System of Michigan now owns 9,570 shares of the biotechnology company’s stock worth $392,000 after acquiring an additional 350 shares during the last quarter. Finally, Texas Permanent School Fund grew its holdings in Regenxbio by 2.0% in the 3rd quarter. Texas Permanent School Fund now owns 21,294 shares of the biotechnology company’s stock worth $758,000 after acquiring an additional 408 shares during the last quarter. 78.43% of the stock is currently owned by institutional investors and hedge funds.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Read More: What are the qualifications of a portfolio manager?

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Phoenix Tree  Coverage Initiated by Analysts at Jefferies Financial Group
Phoenix Tree Coverage Initiated by Analysts at Jefferies Financial Group
Brookfield Infrastructure Partners  Given “In-Line” Rating at BMO Capital Markets
Brookfield Infrastructure Partners Given “In-Line” Rating at BMO Capital Markets
Crowdstrike  Lifted to Buy at DA Davidson
Crowdstrike Lifted to Buy at DA Davidson
Facebook  Downgraded by Pivotal Research
Facebook Downgraded by Pivotal Research
Boston Beer  Upgraded at Credit Suisse Group
Boston Beer Upgraded at Credit Suisse Group
Virtu Financial  Downgraded by TheStreet to D+
Virtu Financial Downgraded by TheStreet to D+


 
© 2006-2020 Zolmax.